Compare BZFD & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZFD | MURA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | BZFD | MURA |
|---|---|---|
| Price | $1.01 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 427.9K | 224.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $184,927,000.00 | N/A |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $394.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.95 |
| 52 Week High | $4.40 | $4.74 |
| Indicator | BZFD | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 40.39 |
| Support Level | $0.95 | $2.06 |
| Resistance Level | $1.33 | $2.10 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 28.09 | 25.00 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.